Intraperitoneal Ropivacaine Nebulization for Pain Control After Laparoscopic Surgery

NCT ID: NCT01143025

Last Updated: 2011-05-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

165 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess if intraperitoneal nebulization of Ropivacaine 50 mg, 100 mg or 150 mg may prevent the use of morphine during the first day after laparoscopic cholecystectomy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Intraperitoneal aerosolization of Bupivacaine 50 mg after laparoscopic cholecystectomy has been proved to significantly reduce postoperative pain, morphine consumption and incidence of postoperative nausea and vomiting in comparison with patients receiving direct instillation of Bupivacaine 50 mg or placebo.

Ropivacaine can be effectively administrated with non-heating nebulizers (AeronebPro®). In a recent study our group found that nebulization of Ropivacaine 30 mg with the AeronebPro® before or after laparoscopic cholecystectomy significantly reduced postoperative pain and morphine consumption. Nonetheless, most patients still need strong opioid based analgesia after surgery.

We hypothesize that intraperitoneal nebulization of Ropivacaine 100 mg and 150 mg (maximum recommended dose in adults 300 mg or up to 3 mg/kg) may prevent the use of morphine during the first day after surgery maintaining ropivacaine plasma levels below toxic concentration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Laparoscopic Cholecystectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ropivacaine 50 mg

Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity

Group Type ACTIVE_COMPARATOR

Ropivacaine 50 mg

Intervention Type DRUG

Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity

Ropivacaine 100 mg

Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity

Group Type EXPERIMENTAL

Ropivacaine 100 mg

Intervention Type DRUG

Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity

Ropivacaine 150 mg

Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity

Group Type EXPERIMENTAL

Ropivacaine 150 mg

Intervention Type DRUG

Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ropivacaine 50 mg

Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity

Intervention Type DRUG

Ropivacaine 100 mg

Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity

Intervention Type DRUG

Ropivacaine 150 mg

Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nebulization Ropivacaine Nebulization Ropivacaine Nebulization Ropivacaine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females and Males 18-75 years old
* ASA Score I-III
* Scheduled for laparoscopic cholecystectomy
* Free from pain in preoperative period
* Not using analgesic drugs before surgery
* Without cognitive impairment or mental retardation
* Written informed consent

Exclusion Criteria

* Emergency/urgency surgery
* Postoperative admission in an intensive care unit
* Cognitive impairment or mental retardation
* Progressive degenerative diseases of the CNS
* Seizures or chronic therapy with antiepileptic drugs
* Severe hepatic or renal impairment
* Pregnancy or lactation
* Allergy to one of the specific drugs under study
* Acute infection or inflammatory chronic disease
* Alcohol or drug addiction
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Milano Bicocca

OTHER

Sponsor Role collaborator

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

Sponsor Role collaborator

Azienda L'ULSS 15 Alta Padovana

OTHER

Sponsor Role collaborator

Gruppo Ospedaliero San Donato, Policlinico San Pietro, Ponte San Pietro, Bergamo

UNKNOWN

Sponsor Role collaborator

Azienda U.S.L. della Valle d'Aosta, Ospedale Regionale Umberto Parini

UNKNOWN

Sponsor Role collaborator

San Gerardo Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

First Service of anesthesia and intensive care. San Gerardo Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Massimo Allegri, MD

Role: STUDY_CHAIR

Servizio Anestesia e Rianimazione I e Terapia del Dolore, Fondazione IRCCS Policlinico San Matteo, Pavia

Mario Regazzi, MD

Role: STUDY_CHAIR

Head of Clinical PK and TDM Laboratory, Foundation IRCCS Policlinico San Matteo, Pavia

Ernesto Pizzirani, MD

Role: STUDY_CHAIR

U.O.C. Anestesia e Rianimazione. A.O. U.L.S.S.15 "Alta Padovana", Presidio Camposampiero. Camposampiero - Padova

Fiorenza Franceschi, MD

Role: STUDY_CHAIR

U.O.C. Anestesia e Rianimazione. A.O. U.L.S.S.15 "Alta Padovana", Presidio Camposampiero. Camposampiero - Padova

Armando Alborghetti, MD

Role: STUDY_CHAIR

U.O.C. Anestesia e Rianimazione. Ospedale di Ponte San Pietro. Bergamo

Alessandro Albani, MD

Role: STUDY_CHAIR

U.O. Anestesia e Rianimazione. Ospedale Regionale "U. Parini", Aosta

Pierre Diemusch, MD

Role: STUDY_CHAIR

Servizio di Anestesia e rianimazione chirurgica. Hospital de Hautepierre. Università di Strasburgo.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

San Gerardo Hospital

Monza, MB, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

Greib N, Schlotterbeck H, Dow WA, Joshi GP, Geny B, Diemunsch PA. An evaluation of gas humidifying devices as a means of intraperitoneal local anesthetic administration for laparoscopic surgery. Anesth Analg. 2008 Aug;107(2):549-51. doi: 10.1213/ane.0b013e318176fa1c.

Reference Type BACKGROUND
PMID: 18633034 (View on PubMed)

Schlotterbeck H, Schaeffer R, Dow WA, Diemunsch P. Cold nebulization used to prevent heat loss during laparoscopic surgery: an experimental study in pigs. Surg Endosc. 2008 Dec;22(12):2616-20. doi: 10.1007/s00464-008-9841-z. Epub 2008 Mar 18.

Reference Type BACKGROUND
PMID: 18347861 (View on PubMed)

Alkhamesi NA, Peck DH, Lomax D, Darzi AW. Intraperitoneal aerosolization of bupivacaine reduces postoperative pain in laparoscopic surgery: a randomized prospective controlled double-blinded clinical trial. Surg Endosc. 2007 Apr;21(4):602-6. doi: 10.1007/s00464-006-9087-6. Epub 2006 Dec 16.

Reference Type RESULT
PMID: 17180268 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AR HSG 01 2010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pain Reduction After Cholecystectomy
NCT01199406 COMPLETED PHASE4
Study of Postoperative ICC Analgesia
NCT04939545 COMPLETED PHASE3
Perioperative Intravenous Lidocaine in Liver Surgery
NCT05153785 COMPLETED PHASE2/PHASE3